Short PR Intervals and Tachyarrhythmias in Fabry's Disease
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Some Observations on the Atrial Sound*
15 Oktober 1960 S.A. TYDSKRIF VIR GENEESKUNDE 887 SOME OBSERVATIONS ON THE ATRIAL SOUND* JOHN R BARLOW, M.R, RCH., M.R.C.P., Department of Medicine, University of The WiTwaTersralld. Johallllesburg The atrial sound, also known as the fourth heart sound Emotional factors probably play a large part in this; the or. presystolic gallop, has been defined' as an audible P-G interval may quickly horten again on the introduction ibration occurring more than 0·07 second after the of an intravenous needle or imilar procedure. beginning of the P wave of the simultaneous electrocardio 3. EffeCT of respiration. Whereas re piration produce gram (ECG) but preceding the onset of the QRS complex. no effect on the P-G interval in patients with hyperten ion It has been shown' that, unrelated to any alteration in the or ischaemia. the atrial sound of cor pulmonale both in P-R interval, the position of the atrial sound varies in creases in intensity and occurs earlier in the cardiac cycle relation to the first heart sound and to the simultaneous during inspiration as compared with expiration (Fig. 4). ECG. 4. EffeCT of various procedures. Jt has already been Jt is the purpose of this paper to demonstrate this mentioned that the intravenous administration of hypo variation in the timing of the atrial sound and to discuss tensive drugs will increase the P-G interval in hypertensive some of the clinical implications resulting from this varia patients. The inhalation of amyl nitrite has a similar effect bility. in hypertension (Fig. 5), though a change in the P-G METHODS AND OBSERVATIO S interval is seldom seen in cases with ischaemic heart disease following inhalation of this drug. -
Chronotropic and Dromotropic Responses to Localized Glutamate Microinjections in the Rat $ Nucleus Ambiguus
brain research 1542 (2014) 93–103 Available online at www.sciencedirect.com www.elsevier.com/locate/brainres Research Report Chronotropic and dromotropic responses to localized glutamate microinjections in the rat $ nucleus ambiguus Karla N. Sampaio1,He´lder Mauad2, K. Michael Spyer, Timothy W. Fordn Division of Biosciences, Faculty of Life Sciences, University College London, Gower Street, London WC1E 6BT, UK article info abstract Article history: The cardioinhibitory effects of cardiac vagal motoneurons (CVMs) are mediated by Accepted 18 October 2013 activation of postganglionic neurons in the epicardial ganglia which have been shown to Available online 24 October 2013 exert functionally selective effects on heart rate and atrioventricular conduction in the rat. Here we investigate whether CVMs producing these responses may occupy different Keywords: rostrocaudal positions within the nucleus ambiguus. Excitation of CVMs was attempted Autonomic nervous system by microinjections of glutamate into the nucleus ambiguus of an arterially perfused Vagus nerve preparation in a grid extending over 2 mm in the rostrocaudal plane using the obex as a Nucleus ambiguus reference point. Microinjections were paired, one made during pacing to measure changes Heart rate in atrioventricular conduction (P-R interval) independent of changes in heart rate and the Glutamate other looking for changes in heart period (P-P interval) un-paced. Although evidence of a differential distribution was found in 7 cases, in the majority (13/20), sites producing maximal effects on both variables coincided. Maximal changes in atrioventricular conduc- tion resulted from more rostral sites in 6 cases and from a more caudal site in only one. Overall, the ratio of the change in atrioventricular conduction to the change in heart rate for a given site was significantly greater 1 mm rostral to the obex than at either end of the test grid. -
Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1. -
Management of Patients with Cardiac Manifestations
MANAGEMENT OF PATIENTS WITH CARDIAC MANIFESTATIONS KDIGOAleš Linhart First School of Medicine Charles University Prague Czech Republic Disclosure of Interests Speaker´s honoraria, travel reimbursements and consultancy honoraria from: • Genzyme • Shire HGT • Amicus Therapeutics • Actelion KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland KDIGO HEART FAILURE KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Diffuse LVH on MRI in Fabry disease KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Data source: General University Hospital, Prague Cardiac symptoms in AFD LV hypertrophy absent LV hypertrophy present KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Linhart et al., European Heart Journal 2007 28(10):1228-1235 Fabry left ventricular function KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland N-Terminal Pro-BNP in Diagnosis of Cardiac Involvement in AFD Patients 117 patients, (age 48 ± 15 years, 46.2% men) - BNP elevated in 57% KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Coats et al., Am J Cardiol. 2013;111:111-7. Diagnosis of heart failure KDIGO ESC GuidelinesKDIGO Controversies for the Conference diagnosis on Fabry and Disease treatment | October of 15-17, acute 2015 and | Dublin, chronic Ireland heart failure 2012. European Heart Journal 2012; 33: 1787–1847 Trials in heart failure with preserved ejection fraction DIG-PEF Digoxin Trend to ↓ hospitalizations ↑ UAP CHARM-PRESERVED Candesartan Trend ↓ hospitalizations I-PRESERVE Irbesartan No effect PEP-CHF PerindoprilKDIGO↓ hospitalizations SENIORS HF-PEF Nebivolol Trend to ↓ Clinical subgroup complications TOP-CAT Spironolactone Effective in subjects recruited in USA and LATAM KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland J Am Coll Cardiol. -
Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified A-Galactosidase from Ficin
Pediat. Res. 7: 684-690 (1973) Fabry's disease genetic disease ficin trihexosylceramide a-galactosidase Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified a-Galactosidase from Ficin GLYN DAWSON1341, REUBEN MATALON, AND YU-TEH LI Departments of Pediatrics and Biochemistry, Joseph P. Kennedy, Jr., Mental Retardation Research Center, University of Chicago, Chicago, Illinois, USA Extract Cultured skin fibroblasts from patients with Fabry's disease showed the characteristic a-galactosidase deficiency and accumulated a four- to sixfold excess of trihexosylceram- ide (GL-3). To demonstrate the correction, cells previously labeled with U-14G-glucose were grown in medium containing a purified a-galactosidase preparation obtained from ficin. The results demonstrated that a-galactosidase was taken up rapidly from the medium and that, despite its apparent instability in the fibroblasts, it was able to become incorporated into lysosomes and catabolize the stored trihexosylceramide. These findings support the reports of therapeutic endeavors by renal transplantation and plasma infusion in Fabry's disease and suggest the extension of such studies to other related disorders in which the cultured skin fibroblasts are chemically abnormal, namely, Gaucher's disease, lactosylceramidosis, and GM2-gangliosidosis type II. Speculation It may be possible to replace the specific missing lysosomal hydrolase in various sphingolipidoses and other storage diseases. Although we do not propose to effect enzyme replacement therapy in vivo with a plant enzyme, such studies in tissue culture are valid, and eventually human a-galactosidase, of comparable activity and purity, will become available. Introduction tially unaffected, periodic crises of pain occur and this may be explained by the accumulation of GL-3 in the Fabry's disease (angiokeratoma corporis diffusum uni- dorsal root ganglia [21, 23]. -
Basic Rhythm Recognition
Electrocardiographic Interpretation Basic Rhythm Recognition William Brady, MD Department of Emergency Medicine Cardiac Rhythms Anatomy of a Rhythm Strip A Review of the Electrical System Intrinsic Pacemakers Cells These cells have property known as “Automaticity”— means they can spontaneously depolarize. Sinus Node Primary pacemaker Fires at a rate of 60-100 bpm AV Junction Fires at a rate of 40-60 bpm Ventricular (Purkinje Fibers) Less than 40 bpm What’s Normal P Wave Atrial Depolarization PR Interval (Normal 0.12-0.20) Beginning of the P to onset of QRS QRS Ventricular Depolarization QRS Interval (Normal <0.10) Period (or length of time) it takes for the ventricles to depolarize The Key to Success… …A systematic approach! Rate Rhythm P Waves PR Interval P and QRS Correlation QRS Rate Pacemaker A rather ill patient……… Very apparent inferolateral STEMI……with less apparent complete heart block RATE . Fast vs Slow . QRS Width Narrow QRS Wide QRS Narrow QRS Wide QRS Tachycardia Tachycardia Bradycardia Bradycardia Regular Irregular Regular Irregular Sinus Brady Idioventricular A-Fib / Flutter Bradycardia w/ BBB Sinus Tach A-Fib VT PVT Junctional 2 AVB / II PSVT A-Flutter SVT aberrant A-Fib 1 AVB 3 AVB A-Flutter MAT 2 AVB / I or II PAT PAT 3 AVB ST PAC / PVC Stability Hypotension / hypoperfusion Altered mental status Chest pain – Coronary ischemic Dyspnea – Pulmonary edema Sinus Rhythm Sinus Rhythm P Wave PR Interval QRS Rate Rhythm Pacemaker Comment . Before . Constant, . Rate 60-100 . Regular . SA Node Upright in each QRS regular . Interval =/< leads I, II, . Look . Interval .12- .10 & III alike .20 Conduction Image reference: Cardionetics/ http://www.cardionetics.com/docs/healthcr/ecg/arrhy/0100_bd.htm Sinus Pause A delay of activation within the atria for a period between 1.7 and 3 seconds A palpitation is likely to be felt by the patient as the sinus beat following the pause may be a heavy beat. -
Electrocardiography: a Technologist's Guide to Interpretation
CONTINUING EDUCATION Electrocardiography: A Technologist’s Guide to Interpretation Colin Tso, MBBS, PhD, FRACP, FCSANZ1,2, Geoffrey M. Currie, BPharm, MMedRadSc(NucMed), MAppMngt(Hlth), MBA, PhD, CNMT1,3, David Gilmore, ABD, CNMT, RT(R)(N)3,4, and Hosen Kiat, MBBS, FRACP, FACP, FACC, FCCP, FCSANZ, FASNC, DDU1,2,3,5 1Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia; 2Cardiac Health Institute, Sydney, New South Wales, Australia; 3Faculty of Science, Charles Sturt University, Wagga Wagga, New South Wales, Australia; 4Faculty of Medical Imaging, Regis College, Boston, Massachusetts; and 5Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than December 2018. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive 1.0 CEH (Continuing Education Hour) credit. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test. foundation for understanding the science of electrocardiog- The nuclear medicine technologist works with electrocardio- raphy and its interpretation. graphy when performing cardiac stress testing and gated cardiac imaging and when monitoring critical patients. -
Basic Cardiac Rhythms – Identification and Response Module 1 ANATOMY, PHYSIOLOGY, & ELECTRICAL CONDUCTION Objectives
Basic Cardiac Rhythms – Identification and Response Module 1 ANATOMY, PHYSIOLOGY, & ELECTRICAL CONDUCTION Objectives ▪ Describe the normal cardiac anatomy and physiology and normal electrical conduction through the heart. ▪ Identify and relate waveforms to the cardiac cycle. Cardiac Anatomy ▪ 2 upper chambers ▪ Right and left atria ▪ 2 lower chambers ▪ Right and left ventricle ▪ 2 Atrioventricular valves (Mitral & Tricuspid) ▪ Open with ventricular diastole ▪ Close with ventricular systole ▪ 2 Semilunar Valves (Aortic & Pulmonic) ▪ Open with ventricular systole ▪ Open with ventricular diastole The Cardiovascular System ▪ Pulmonary Circulation ▪ Unoxygenated – right side of the heart ▪ Systemic Circulation ▪ Oxygenated – left side of the heart Anatomy Coronary Arteries How The Heart Works Anatomy Coronary Arteries ▪ 2 major vessels of the coronary circulation ▪ Left main coronary artery ▪ Left anterior descending and circumflex branches ▪ Right main coronary artery ▪ The left and right coronary arteries originate at the base of the aorta from openings called the coronary ostia behind the aortic valve leaflets. Physiology Blood Flow Unoxygenated blood flows from inferior and superior vena cava Right Atrium Tricuspid Valve Right Ventricle Pulmonic Valve Lungs Through Pulmonary system Physiology Blood Flow Oxygenated blood flows from the pulmonary veins Left Atrium Mitral Valve Left Ventricle Aortic Valve Systemic Circulation ▪ Blood Flow Through The Heart ▪ Cardiology Rap Physiology ▪ Cardiac cycle ▪ Represents the actual time sequence between -
JUGULAR VENOUS PRESSURE Maddury Jyotsna
INDIAN JOURNAL OF CARDIOVASCULAR DISEASES JOURNAL in women (IJCD) 2017 VOL 2 ISSUE 2 CLINICAL ROUNDS 1 WINCARS JVP- JUGULAR VENOUS PRESSURE Maddury Jyotsna DEFINITION OF JUGULAR VENOUS PULSE AND The external jugular vein descends from the angle of the PRESSURE mandible to the middle of the clavicle at the posterior Jugular venous pulse is defined as the oscillating top of border of the sternocleidomastoid muscle. The external vertical column of blood in the right Internal Jugular jugular vein possesses valves that are occasionally Vein (IJV) that reflects the pressure changes in the right visible. Blood flow within the external jugular vein is atrium in cardiac cycle. In other words, Jugular venous nonpulsatile and thus cannot be used to assess the pressure (JVP) is the vertical height of oscillating column contour of the jugular venous pulse. of blood (Fig 1). Reasons for Internal Jugular Vein (IJV) preferred over Fig 1: Schematic diagram of JVP other neck veins are IJV is anatomically closer to and has a direct course to right atrium while EJV does not directly drain into Superior vena cava. It is valve less and pulsations can be seen. Due to presence of valves in External Jugular vein, pulsations cannot be seen. Vasoconstriction secondary to hypotension (as in congestive heart failure) can make EJV small and barely visible. EJV is superficial and prone to kinking. Partial compression of the left in nominate vein is usually relieved during modest inspiration as the diaphragm and the aorta descend and the pressure in the two internal -
The Clinical Landscape for AAV Gene Therapies
https://doi.org/10.1038/d41573-021-00017-7 Supplementary information The clinical landscape for AAV gene therapies In the format provided by the authors Nature Reviews Drug Discovery | www.nature.com/nrd Supplementary Table | Gene therapy trials in the analysis dataset AAVDB NCT Number Title Drug ID Status No of Vector Safety Efficacy met Administration Therapeutic Phases Primary pts met route area Completion 1 NCT02341807 Safety and Dose Escalation Study of SPK-7001 Active, not 10 AAV2 Yes No Subretinal Ophthalmology Phase 1/2 01/10/2019 AAV2-hCHM in Subjects With CHM recruiting (Choroideremia) Gene Mutations 3 NCT02396342 Trial of AAV5-hFIX in Severe or Moderately AMT-061 Active, not 10 AAV5 Yes Yes Intravenous Hematology Phase 1/2 01/05/2021 Severe Hemophilia B recruiting 4 NCT01637805 Clinical Safety and Preliminary Efficacy of NA Unknown 20 NA NA Oncology Phase 1 01/10/2016 AAV-DC-CTL Treatment in Stage IV Gastric status Cancer 6 NCT03496012 Efficacy and Safety of AAV2-REP1 for the BIIB-111 Recruiting 14 AAV2 Yes Yes Subretinal Ophthalmology Phase 3 31/03/2020 Treatment of Choroideremia 7 NCT03252847 Gene Therapy for X-linked Retinitis A-004 Recruiting 36 AAV2 NA NA NA Ophthalmology Phase 1/2 01/11/2020 Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR) 9 NCT03758404 Gene Therapy for Achromatopsia (CNGA3) A-003 Recruiting 18 AAV2 NA NA NA Ophthalmology Phase 1/2 01/05/2021 10 NCT02418598 AADC Gene Therapy for Parkinson’s Disease AAV-hAADC-2 Terminated 2 AAV2 NA NA Intracranial Neurology Phase 1/2 31/03/2018 11 NCT03533673 AAV2/8-LSPhGAA in Late-Onset Pompe ACTUS-101 Recruiting 6 AAV2/8 NA NA Intravenous Metabolic Phase 1/2 01/12/2019 Disease 12 NCT03374202 VRC 603: A Phase I Dose-Escalation Study of AA8-VRC07 Recruiting 25 AAV8 NA NA Intravenous Virology Phase 1 01/01/2020 the Safety of AAV8-VRC07 (VRC-HIVAAV070- 00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral -Treated, HIV-1 Infected Adults With Controlled Viremia. -
Vectorcardiographic Changes During Extended Space Flight
VECTORCARDIOGRAPHIC CHANGES DURING EXTENDED SPACE FLIGHT Raphael F. Smith, M. D. *; Kevin Stanton, M. D. T; David Stoop, M. D. ?; L J. Donald Brown, M.D. 1; Walter Janusz, M.D. and Paul King, Ph.D. * AB ST RACT To assess the effects of space flight on cardiac electrical properties, vectorcardiogram5 were taken on the 9 Skylab astronauts during the flights of 28, 59, and 84 days. The Frank lead system was used and observations were made at rest; during 25%, 50%, and 75% of maximum exercise; during a short pulse of exercise (150 watts, 2 minutes); and after exercise. Data from 131 in-flight tests were analyzed by computer and compared to preflight and postflight values. Statistic- ally significant increase in QRS vector magnitude (six of nine crew- men); T vector magnitude (five of nine crewmen); and resting PR interval duration (six of nine crewmen) occurred. During exercise the PR interval did not differ from preflight. Exercise heart rates in- flight were the same as preflight, but increased in the immediate postflight period. No wajor changes in QRS, T, or ST vector direction occurred. There were sporadic (usual ly i sol ated) ectopic ventri cul ar beats in-flight and one astronaut had a brief episode of ventricular tachycardia 21 days after the first mission. Conclusions: with the exception of the arrhythmias, no deleterious vectorcardiographic changes were observed during the Skylab missions. The increase in QRS and T magnitude resembles the electrocardiographic changes associated with athletic conditioning and may be related to increased ventricular volume secondary to centripetal shifts of fluid and/or the in-flight isotonic exercise program. -
Exercise, the Electrocardiogram, and Peripheral Circulation
iWorx Physiology Lab Experiment Experiment HH-3 Exercise, the Electrocardiogram, and Peripheral Circulation Note: The lab presented here is intended for evaluation purposes only. iWorx users should refer to the User Area on www.iworx.com for the most current versions of labs and LabScribe2 Software. iWorx Systems, Inc. www.iworx.com iWorx Systems, Inc. 62 Littleworth Road, Dover, New Hampshire 03820 (T) 800-234-1757 / 603-742-2492 (F) 603-742-2455 LabScribe2 is a trademark of iWorx Systems, Inc. ©2013 iWorx Systems, Inc. Experiment HH-3: Exercise, the Electrocardiogram, and Peripheral Circulation Background The arterial system functions as a pressure reservoir. Blood enters via the heart and exits through the capillaries. Signals from the autonomic nervous system control the tone of smooth muscle sphincters around the arterioles. In this way, the autonomic nervous system can control the distribution of blood to the various organs in the body. The distribution of blood that flows to a particular organ is influenced by local conditions. If there are cells that require arterial blood, due to a decline in pH or oxygen levels or an increase in carbon dioxide levels, smooth muscle sphincters open to permit blood into particular capillary beds. At rest, the distribution of blood to a particular organ may be very different from that seen during exercise. For example, the blood flow to the gut decreases during exercise, while blood flow to the skeletal muscles increases dramatically. Furthermore, the amount of blood flowing around the circulatory system may be increased several fold. In this laboratory you will record the electrocardiogram and the finger pulse from a (healthy) subject.